Nursing · Independent exam preparation

CPHON® Pediatric Hematology and Oncology Decision Guide Study Guide

Practise pediatric hematology and oncology decisions: recognize emergencies, connect treatments with toxicities, plan survivorship, and support children and families.

By CertMedbry · Updated 27 October 2026

60 concepts explainedWorked examples & common pitfallsOfficial blueprint references

Recognize urgent deterioration, distinguish treatment toxicities, interpret diagnostic evidence, and plan care around a child's development and treatment exposures. This guide supports registered nurses preparing for ONCC's Certified Pediatric Hematology Oncology Nurse examination. Its 60 selected concepts connect mechanisms with practical decisions across all six domains. The official CPHON Test Content Outline defines the full examination scope; use it to identify additional topics beyond this selective guide.

Try 20 free practice questions

What is the exam format?

Check the question types, timing and outline before planning your revision.

Which credential and professional level does this guide cover?

This guide covers ONCC's Certified Pediatric Hematology Oncology Nurse, CPHON®, for registered nurses practicing pediatric hematology/oncology. AOCNP® is a separate adult oncology nurse-practitioner credential. TCTCN™, formerly BMTCN®, is a separate transplantation and cellular therapy nursing credential covering adult or pediatric practice. Their examinations and blueprints should not be substituted for CPHON.

2026 ONCC Certification Test Registration Manual

How many questions are scored, and what item style is used?

The 2026 manual specifies 165 multiple-choice questions: 125 scored questions and 40 unidentified pretest or experimental questions. Each question has four answer options and one correct answer. These 20 independent learning questions use that single-best-answer structure without claiming to reproduce official items.

2026 ONCC Certification Test Registration Manual

How long is the testing session?

The session lasts three hours and includes the computer tutorial and post-test survey. There are no scheduled breaks; the session timer continues during a candidate's break. Plan pacing around the entire session rather than assuming three hours exclusively for answering questions.

2026 ONCC Certification Test Registration Manual

Where is the examination delivered, and is it adaptive?

The manual describes computer-based testing at PSI test centers. Testing is available year-round in the United States, its territories, and Canada; international testing has a separate limited annual window. Computer-adaptive delivery is not specified in the cited issuer information. These drills are a fixed educational set.

2026 ONCC Certification Test Registration Manual

Which blueprint applies, and why are six domains used?

The 2026 registration manual is valid beginning January 1, 2026. Its six-domain CPHON blueprint matches the standalone outline linked by ONCC in October 2026. That outline has a 2025 filename and copyright 2024, but no explicit effective date in its text. The older outline explicitly marked Effective 2023 establishes continuity only. Although the credential webpage says five subject areas, the current manual and linked outline both specify six.

2026 ONCC Certification Test Registration Manual · CPHON Test Content Outline · CPHON Test Content Outline — Effective 2023 · Certified Pediatric Hematology Oncology Nurse (CPHON®) | ONCC

What are the domain weights and this guide's allocations?

The official weights are Care Continuum 6%; Pediatric Hematology and Oncology Nursing Practice 18%; Treatment Modalities and Side Effects 21%; Symptom Management and Supportive Care 26%; Pediatric Hematologic and Oncologic Emergencies 21%; and Psychosocial Dimensions of Care 8%. The 60 concepts allocate 4, 11, 12, 16, 12, and 5 entries, respectively. Questions and flashcards each allocate 1, 4, 4, 5, 4, and 2 entries. These rounded allocations approximate the blueprint.

CPHON Test Content Outline · 2026 ONCC Certification Test Registration Manual

Which eligibility and jurisdiction boundaries should candidates check?

The 2026 manual requires an active, unencumbered RN license in the United States, its territories, or Canada; at least two years of RN experience and 2,000 hours of pediatric hematology or oncology nursing practice within the preceding four years; and qualifying specialty education within the preceding three years. Candidates licensed elsewhere require the issuer's credential-evaluation process. Consult ONCC for the applicable international arrangements rather than assuming domestic eligibility or scheduling rules apply worldwide.

2026 ONCC Certification Test Registration Manual

Independent educational material for the CPHON registered-nurse specialty examination. The questions are original learning drills, and results do not predict certification performance.

Outline used: Verified against the 2026 ONCC Certification Test Registration Manual, valid January 1, 2026, and the CPHON Test Content Outline linked from ONCC's current preparation page on 2026-10-11. The linked outline has a 2025 filename and copyright 2024, without an explicit effective date in its text. Its six domains and weights match the 2026 manual. An earlier official outline explicitly marked Effective 2023 was consulted only to establish version continuity. The workbook label maps directly to this current examination; the assigned canonical slug is preserved.

60 key concepts: understand, apply and avoid the traps

Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.

Care Continuum6%

1.What belongs in an exposure-based survivorship summary?

A survivorship summary links the original diagnosis and treatment history to future health risks. Record relevant chemotherapy agents and cumulative exposures, radiation fields and doses, surgeries, transplantation, and important complications. These details determine which organs need surveillance even when the survivor feels well. The discriminating principle is exposure-based follow-up: two children with the same cancer can need different surveillance because their treatments differed.

Apply it

A young adult remembers having leukemia but cannot name the medicines received. Before arranging long-term follow-up, the nurse obtains the treatment summary and identifies anthracycline exposure, radiation history, and previous complications that affect surveillance.

Common pitfall: Using diagnosis alone to select screening misses treatment-specific risks. A normal current examination also does not erase the possibility of later exposure-related disease.

Children's Oncology Group Long-Term Follow-Up Guidelines, Version 6.0, October 2023

2.How should specialty and primary care share a transition?

A safe transition transfers responsibility as well as information. The receiving clinician needs the diagnosis, treatment summary, current medicines, unresolved problems, exposure-based surveillance plan, and a clear route back to specialty care. Primary care continues routine prevention and management of general health needs while specialty teams address disease-specific risks. Readiness includes the young person's ability to explain their condition and participate in appointments and medication management.

Apply it

An adolescent moving away for college has missed two follow-up visits. The nurse identifies a receiving clinician, transfers the survivorship plan, confirms who will order surveillance, and rehearses how the adolescent will request appointments independently.

Common pitfall: Sending records without confirming a receiving clinician leaves ownership unclear. Transfer readiness should reflect practical skills and support needs, rather than age alone.

Children's Oncology Group Long-Term Follow-Up Guidelines, Version 6.0, October 2023

3.How do late-effect screening and symptom evaluation differ?

Exposure-based screening seeks problems before symptoms appear; diagnostic evaluation investigates a current concern. The Children's Oncology Group long-term follow-up guidelines primarily address asymptomatic survivors and do not replace evaluation of new symptoms. A survivor with exertional breathlessness, persistent bone pain, or a new neurologic deficit needs assessment directed by that symptom and its urgency. A future routine surveillance appointment is not an adequate response to a concerning change.

Apply it

A survivor with previous chest irradiation reports new exertional breathlessness several months before a scheduled follow-up visit. The nurse arranges prompt clinical evaluation instead of treating the existing surveillance appointment as sufficient reassurance for the new symptom.

Common pitfall: A surveillance schedule is not a triage tool. New symptoms require assessment even when previous screening was normal or the next screening date is distant.

Children's Oncology Group Long-Term Follow-Up Guidelines, Version 6.0, October 2023

4.When should goals of care be revisited during progression?

Goals of care should be revisited when disease status, treatment burden, symptoms, or family priorities change. Clarify what the child and family understand, what outcomes matter, and which interventions support those outcomes. Palliative clinicians can help with symptom relief, communication, and coordination while cancer-directed treatment continues. Transition planning should identify the preferred care setting, available support, and how urgent symptoms will be managed across settings.

Apply it

After another relapse, a family wants more time at home while considering further treatment. The nurse coordinates a goals discussion, home symptom support, and clear contact arrangements without assuming the family has chosen to stop cancer therapy.

Common pitfall: Equating palliative involvement with abandonment can delay useful support. A change in treatment goals also does not remove the need for active symptom management.

Palliative Care in Cancer | NCI

Pediatric Hematology and Oncology Nursing Practice18%

5.Why is marrow evaluation important when leukemia is suspected?

Leukemia arises from abnormal blood-forming cells, so marrow examination helps establish the diagnosis and characterize the malignant population. A complete blood count can reveal anemia, thrombocytopenia, or abnormal white cells, but those findings alone do not fully classify leukemia. Marrow morphology, immunophenotyping, and genetic studies provide complementary information. Pallor, bruising, fever, and bone pain together suggest impaired normal hematopoiesis rather than an isolated musculoskeletal problem.

Apply it

A child has fatigue, petechiae, and persistent leg pain with anemia and thrombocytopenia. The nurse explains that marrow testing identifies abnormal blood-forming cells and supports leukemia classification, while the blood count describes its effects on circulating cells.

Common pitfall: A high total white count is not required for leukemia. Reassurance based only on a normal or low white count overlooks other marrow abnormalities.

Childhood Acute Lymphoblastic Leukemia | NCI

6.What does immunophenotyping add to leukemia classification?

Immunophenotyping identifies proteins expressed by abnormal cells and helps determine their lineage and maturation pattern. In acute lymphoblastic leukemia, distinguishing B-lineage from T-lineage disease contributes to accurate classification and treatment planning. Cell appearance alone may not resolve lineage reliably. Immunophenotyping answers what kind of abnormal cell is present; it does not measure the child's pain, establish inherited susceptibility, or replace all molecular and cytogenetic testing.

Apply it

A parent asks why flow cytometry is needed after blasts were seen in marrow. The nurse explains that cell markers help identify the leukemia lineage and that this classification supplies information beyond simply recognizing immature cells.

Common pitfall: Confusing immunophenotyping with routine blood typing obscures its purpose. The test characterizes malignant cells rather than selecting ABO-compatible blood products for transfusion support.

Childhood Acute Lymphoblastic Leukemia | NCI

7.How do leukemia genetics differ from inherited cancer susceptibility?

Genetic changes detected in leukemia cells can help classify disease, estimate prognosis, or identify treatment targets. Such findings do not automatically mean that the change is present in every cell or was inherited from a parent. Germline susceptibility concerns a constitutional predisposition and requires a different interpretation. The key distinction is the tissue and clinical question being tested: tumor-cell biology and inherited family risk are related but separate questions.

Apply it

A parent hears that a chromosome change was found in their child's leukemia and worries that every sibling has it. The nurse clarifies that leukemia-cell findings do not by themselves establish an inherited familial condition.

Common pitfall: Calling every tumor mutation hereditary can create unnecessary fear. Conversely, a tumor-focused result does not exclude a separate inherited predisposition when clinical features suggest one.

Childhood Acute Lymphoblastic Leukemia | NCI

8.How do tumor grade and cancer stage differ?

Tumor grade describes microscopic features, including how abnormal cells look and how differentiated they are. Stage describes disease extent, such as local involvement and spread, using the system applicable to that cancer. A high-grade tumor is not automatically metastatic, and a localized tumor can still have aggressive histology. Classification systems vary by disease; generic solid-tumor staging language should not be imposed on every pediatric leukemia or brain tumor.

Apply it

A family interprets a high-grade pathology report as proof that a tumor has spread throughout the body. The nurse distinguishes microscopic aggressiveness from anatomic extent and explains why staging information is still needed for treatment planning.

Common pitfall: Treating grade and stage as interchangeable misstates prognosis. Neither label alone captures all disease-specific factors, treatment response, or molecular features that influence clinical decisions.

Tumor Grade | NCI

9.What different questions do neuroblastoma diagnostic studies answer?

Neuroblastoma evaluation combines anatomy, biochemical evidence, and tumor biology. CT or MRI defines the primary mass and surrounding structures; MRI is particularly important when paraspinal disease threatens the spinal canal. Urinary VMA and HVA measure catecholamine metabolites. MIBG imaging assesses sites of uptake and disease distribution. Tumor tissue supplies histology and biologic features such as MYCN status for risk assignment. An elevated urine marker alone does not provide this complete classification.

Apply it

A child with a paraspinal mass has elevated urinary catecholamine metabolites. The nurse explains why spinal MRI and tissue characterization remain important: the studies address neural involvement, diagnosis, and biologic risk beyond the biochemical finding.

Common pitfall: A biochemical marker does not establish anatomic extent or replace tumor histology and biology. A negative MIBG study also cannot exclude every neuroblastoma because some tumors are not MIBG avid.

Neuroblastoma Treatment (PDQ®) — Health Professional Version | NCI

10.Why can measurable residual disease matter after apparent remission?

Measurable residual disease (MRD) testing detects leukemia below the level recognized by routine microscopic assessment. Methods include flow cytometry, which identifies abnormal cellular immunophenotypes, and molecular assays, which detect leukemia-associated genetic sequences. A marrow with fewer than 5% blasts can meet the marrow morphologic remission criterion while remaining MRD positive. MRD therefore supplies treatment-response and relapse-risk information beyond morphology or blood-count recovery. Interpretation depends on assay sensitivity, the treatment time point, and the protocol's thresholds and decision rules.

Apply it

After induction, a child's marrow meets the morphologic remission criterion, but flow cytometry detects residual leukemic cells. Explain that the tests measure disease at different levels of sensitivity. The team uses the MRD result at that specified treatment time point, together with other risk features, to determine the protocol-defined treatment pathway.

Common pitfall: Count recovery and morphologic remission do not establish eradication of every leukemic cell. Likewise, an MRD-negative result means disease was not detected within that assay's sensitivity; it does not prove that no leukemia remains. Avoid applying one protocol's MRD threshold or treatment decision to another protocol.

Childhood Acute Lymphoblastic Leukemia Treatment (PDQ®) - NCI

11.What distinguishes hemophilia A from hemophilia B?

Hemophilia A involves deficient or dysfunctional factor VIII, whereas hemophilia B involves factor IX. Both impair effective clot formation and can cause prolonged bleeding or bleeding into joints and muscles. Their usual inheritance is X-linked, although a family history may be absent. The factor deficiency matters because replacement treatment must address the relevant protein; similar bleeding symptoms do not make the two deficiencies therapeutically interchangeable.

Apply it

A child newly diagnosed with hemophilia B has an affected maternal uncle. The nurse connects the family pattern with X-linked inheritance and confirms that the care plan identifies factor IX deficiency rather than assuming factor VIII replacement.

Common pitfall: A missing family history does not exclude hemophilia. Also, the disorder concerns coagulation-factor function; a normal platelet count does not establish normal clotting ability.

About Hemophilia | CDC

12.How do the main clinical trial phases differ?

Early-phase trials primarily investigate safety, dose, schedule, and adverse effects. Phase II trials examine whether an intervention shows activity against a particular cancer while continuing safety assessment. Phase III trials compare an intervention with an established approach or other appropriate comparator. These purposes guide the consent discussion: participation in an early-phase study does not establish that the treatment is superior, and later-phase research still carries uncertainty and potential harm.

Apply it

A parent describes a dose-finding study as proof that the new drug works better than standard therapy. The nurse explains the study's safety and dosing objectives and asks the research team to review expected benefits and uncertainties.

Common pitfall: Treating a trial phase as a guarantee of personal benefit creates therapeutic misconception. Study purpose describes the research question, not the outcome for an individual child.

How Do Clinical Trials Work? | NCI

13.How do baseline hemoglobin and reticulocytes guide sickle-cell anemia assessment?

Interpret hemoglobin against the child's usual value because baseline anemia varies across sickle-cell genotypes and treatments. A decline of at least 2 g/dL below baseline warrants assessment for an acute complication. The reticulocyte count helps distinguish reduced production from loss, destruction, or sequestration. Markedly reduced reticulocytes with worsening anemia suggest marrow suppression, including a parvovirus-associated aplastic episode; sudden splenic enlargement instead raises concern for sequestration. Symptoms and examination determine urgency alongside laboratory findings.

Apply it

A child with sickle cell disease has worsening pallor, a hemoglobin substantially below baseline, and very few reticulocytes. The nurse reports concern for impaired red-cell production and communicates recent illness and exposure history while arranging urgent assessment.

Common pitfall: A low hemoglobin should not be dismissed as usual sickle-cell anemia without comparison with baseline. The reticulocyte result directs the differential but does not independently establish the cause.

56-364NFULL.pdf

14.How should parental permission and child assent work together?

Research participation requires an informed, voluntary process with protections appropriate to children. Parents or authorized representatives provide permission when required, while children should receive developmentally appropriate explanations and provide assent when applicable. Consent is an ongoing discussion, especially when important new information emerges. The child's questions, understanding, and concerns deserve attention. A signature documents part of the process but does not demonstrate comprehension or justify bypassing a protocol's assent requirements.

Apply it

A study requires assent from developmentally capable adolescents. A parent signs permission while the adolescent remains confused and reluctant. The nurse pauses enrollment steps and requests a discussion that addresses the adolescent's understanding and the protocol's requirements.

Common pitfall: Parental enthusiasm does not substitute for required assent. Conversely, avoid assuming a universal legal age rule when protocol requirements and jurisdiction-specific protections govern participation.

Are Clinical Trials Safe? | NCI

15.How can education reveal whether a family can act safely?

Useful education tests the family's ability to perform the next decision, rather than merely remember terminology. Give clear, developmentally appropriate information, demonstrate practical tasks, and ask caregivers to explain or show the plan in their own words. For urgent symptoms, teach what to recognize, whom to contact, and what action to take. A caregiver's question or incorrect demonstration identifies an opportunity to adjust teaching before discharge.

Apply it

Before discharge, a caregiver correctly names the child's diagnosis but cannot explain what to do for fever. The nurse rehearses the actual call and assessment plan, then asks the caregiver to repeat the action sequence independently.

Common pitfall: Asking whether everything is understood often elicits agreement without demonstrating competence. Extensive written material cannot compensate for an unclear urgent-action plan or unresolved practical barriers.

Support for Families: Childhood Cancer | NCI · Fever and Suspected or Confirmed Neutropenia | Royal Children's Hospital Melbourne

Treatment Modalities and Side Effects21%

16.Why does ALL treatment continue after induction remission?

ALL treatment uses phases because initial remission does not establish that every leukemic cell has been eliminated. Induction aims to achieve remission, subsequent intensive therapy addresses remaining disease, and maintenance sustains antileukemic treatment over time. CNS-directed treatment addresses disease in a compartment requiring specific therapy. Phase names and schedules vary by protocol, but the central principle remains: improved symptoms and blood counts do not justify stopping prescribed treatment.

Apply it

A child feels well after induction, and the family asks whether further treatment is optional. The nurse explains the purpose of subsequent phases and connects continued therapy with controlling leukemia that may remain despite visible clinical improvement.

Common pitfall: Using symptom resolution as the stopping rule ignores residual disease. Treatment phases should be explained by their purpose rather than memorized as interchangeable calendar labels.

Childhood Acute Lymphoblastic Leukemia | NCI

17.Why does ALL require CNS-directed treatment?

Leukemia cells can involve the central nervous system, where many systemically administered medicines do not reach adequate concentrations. CNS-directed treatment therefore has a distinct role in preventing or treating involvement of this compartment. Intrathecal chemotherapy delivers selected medicines into cerebrospinal fluid, and some systemic agents also contribute. Route-specific safety is essential: vincristine is for intravenous use only, and intrathecal administration can be fatal.

Apply it

A family questions why lumbar punctures with treatment are planned when no neurologic symptoms are present. The nurse explains CNS-directed prevention and separately verifies that each medicine and route match the prescribed protocol before administration proceeds.

Common pitfall: Absence of neurologic symptoms does not eliminate the need for protocol-directed CNS prevention. Never infer that every leukemia medicine is suitable for intrathecal administration.

Childhood Acute Lymphoblastic Leukemia | NCI · Vincristine Sulfate Injection — Prescribing Information | DailyMed

18.Which findings suggest vincristine neurotoxicity?

Vincristine disrupts microtubule function and can injure peripheral and autonomic nerves. Peripheral toxicity may appear as weakness, altered gait, reduced reflexes, or sensory symptoms; autonomic toxicity can cause constipation and ileus. Assess bowel function and functional changes together rather than treating them as unrelated complaints. A child who begins tripping and develops progressive constipation after vincristine needs toxicity assessment, even if nausea and blood counts are unremarkable.

Apply it

After several vincristine doses, a child has new difficulty climbing stairs and fewer bowel movements. The nurse assesses gait, strength, abdominal symptoms, and stool history, then reports the combined pattern before the next treatment decision.

Common pitfall: Attributing weakness entirely to inactivity and constipation entirely to diet can miss a shared drug effect. Severe distention or vomiting requires assessment for ileus.

Vincristine Sulfate Injection — Prescribing Information | DailyMed

19.Why does asparaginase require pancreatic and coagulation surveillance?

Asparaginase depletes circulating asparagine, limiting a substrate needed by susceptible leukemia cells. Its effects also create important toxicity risks, including pancreatitis, thrombosis, hemorrhage, hypersensitivity, and metabolic abnormalities. Persistent severe abdominal pain, especially with vomiting, requires evaluation for pancreatitis rather than routine nausea treatment alone. Abnormal coagulation can involve both bleeding and clotting complications, so bruising is not the only relevant warning sign during therapy.

Apply it

A child receiving an asparaginase product develops persistent upper abdominal pain and vomiting. The nurse recognizes a treatment-associated pancreatic warning pattern, promptly informs the team, and prepares for evaluation rather than assuming ordinary chemotherapy-related nausea.

Common pitfall: Calling every gastrointestinal complaint expected toxicity can delay recognition of pancreatitis. Also, an abnormal coagulation profile does not mean the child is protected from thrombosis.

RYLAZE — Prescribing Information | DailyMed

20.How does factor replacement address hemophilia bleeding?

Factor replacement supplies the deficient coagulation protein so clot formation can proceed more effectively. Hemophilia A and B require different factor-specific approaches, and treatment may be used to prevent bleeding or manage an episode. The prescribed product and individual treatment plan matter, particularly when inhibitors interfere with replacement-factor activity. Nursing assessment should connect bleeding location, symptoms, previous treatment response, and the child's established hematology plan.

Apply it

A caregiver reports that a child with hemophilia has received the usual prescribed replacement but joint pain continues to worsen. The nurse escalates the persistent symptoms and communicates the product, administration time, and response to the hematology team.

Common pitfall: Assuming all replacement products are interchangeable ignores the specific deficiency. Persistent bleeding after treatment requires reassessment rather than repeated unsupervised changes to the prescribed plan.

About Hemophilia | CDC

21.How do autologous, allogeneic, and syngeneic transplantation differ?

Autologous transplantation uses the patient's own previously collected blood-forming stem cells. Allogeneic transplantation uses cells from another genetically nonidentical person, including a related or unrelated donor. Syngeneic transplantation uses cells from an identical twin. These classifications describe the relationship between recipient and graft donor, rather than whether cells were collected from peripheral blood, marrow, or umbilical cord blood. Allogeneic donor immune cells can produce beneficial graft-versus-leukemia activity but can also attack recipient tissues, causing graft-versus-host disease.

Apply it

Three children receive peripheral-blood stem cells: one receives their own stored cells, another receives cells from an HLA-matched nonidentical sibling, and the third receives cells from an identical twin. Classify these transplants as autologous, allogeneic, and syngeneic, respectively. Explain donor immune effects and graft-versus-host disease risk when teaching the child receiving the nonidentical sibling's graft.

Common pitfall: A nonidentical sibling's graft remains allogeneic even when HLA matching is favorable. An identical twin's graft is syngeneic. Calling every sibling transplant allogeneic overlooks this distinction, while calling every peripheral-blood transplant autologous confuses the collection site with the donor relationship.

Stem Cell and Bone Marrow Transplants for Cancer | NCI

22.Why does transfusion planning in sickle cell disease consider more than a normal hemoglobin target?

Red-cell transfusion can improve oxygen-carrying capacity, but treatment must also account for the proportion of sickling cells and blood viscosity. Simple transfusion adds donor cells; exchange transfusion removes some patient cells while replacing them with donor cells. Increasing hemoglobin excessively while substantial HbS remains can increase hyperviscosity risk. The prescribed method and target therefore depend on the indication, baseline hemoglobin, and transfusion history rather than a general goal of normalizing the blood count.

Apply it

A caregiver asks for additional red cells because the child's hemoglobin remains below the laboratory reference range. The nurse explains why the hematology team balances oxygen delivery against viscosity and checks the indication-specific target before further transfusion.

Common pitfall: A higher hemoglobin is not always safer in sickle cell disease. Simple and exchange transfusion achieve different changes in red-cell mass and HbS proportion and cannot be substituted casually.

56-364NFULL.pdf

23.How do graft-versus-leukemia and graft-versus-host effects differ?

After allogeneic transplantation, donor immune cells may recognize and attack residual leukemia, producing a beneficial graft-versus-leukemia effect. The same donor immune system can attack healthy recipient tissues, causing graft-versus-host disease. Skin, gastrointestinal tract, and liver involvement are important clinical patterns. The distinction depends on the target of the immune response. New diarrhea or rash is not evidence that leukemia control has improved and requires assessment for toxicity and competing causes.

Apply it

A child develops rash and diarrhea after a donor transplant. A parent believes this means the donor cells are successfully attacking leukemia. The nurse distinguishes the potential antileukemic effect from possible injury to healthy recipient tissues.

Common pitfall: A beneficial donor immune effect does not make graft-versus-host disease desirable. Conversely, suppressing harmful immune activity requires coordinated transplant management rather than independent medication changes.

Stem Cell and Bone Marrow Transplants for Cancer | NCI

24.How do CAR T cells recognize cancer cells?

CAR T-cell therapy modifies T cells to express an engineered receptor that recognizes a selected target on cancer cells. The cells are expanded and infused so they can bind the target and mount an immune response. This differs from simply administering a cytotoxic drug or replacing blood-forming stem cells. Powerful immune activation can also cause serious adverse effects, including cytokine release syndrome, so treatment benefit and inflammatory toxicity must be understood together.

Apply it

A family asks whether CAR T-cell infusion is the same as a stem-cell transplant. The nurse explains that the infused cells are engineered immune effectors directed at a target and reviews why close monitoring follows the infusion.

Common pitfall: The phrase cellular therapy does not make all cell products interchangeable. Engineered target recognition also does not guarantee that every cancer cell will remain susceptible.

T-cell Transfer Therapy | NCI

25.When does surgery serve a different purpose from systemic therapy?

Surgery can obtain diagnostic tissue, remove a localized tumor, or address a specific complication. Systemic treatment addresses disease beyond the operative field and may reduce tumor burden before an operation. In neuroblastoma, surgical decisions depend on disease risk, location, extent, and the danger of injuring adjacent structures. Complete removal is not automatically the safest immediate goal when tumor anatomy makes an operation hazardous or other treatment is needed first.

Apply it

A family asks why a neuroblastoma surrounding major structures is receiving chemotherapy before attempted removal. The nurse explains that shrinking disease and planning around critical anatomy may improve the balance between tumor control and operative harm.

Common pitfall: Assuming earlier or more extensive surgery is always better ignores tumor biology and anatomic risk. A biopsy and a definitive resection also have different purposes.

Neuroblastoma Treatment (PDQ®) — Health Professional Version | NCI

26.What distinguishes iodine-131 MIBG from external-beam radiation?

Iodine-131 MIBG is a radiopharmaceutical that can deliver radiation to neuroblastoma cells that take up MIBG. External-beam radiation directs radiation from a machine toward a planned treatment region. These modalities therefore differ in how radioactive energy reaches tissue and in their care requirements. Demonstrated tumor uptake is relevant to MIBG treatment selection, whereas external-beam planning is based on the prescribed target and surrounding normal structures.

Apply it

A child with neuroblastoma is being considered for iodine-131 MIBG treatment after uptake studies. The nurse explains why tumor uptake matters and prepares the family for a radiopharmaceutical pathway rather than describing an ordinary external-beam appointment.

Common pitfall: Treating every radiation modality as the same procedure can mislead preparation. MIBG eligibility cannot be inferred solely from the presence of a neuroblastoma diagnosis.

Neuroblastoma Treatment (PDQ®) — Health Professional Version | NCI

27.Why does oral maintenance therapy require active medication management?

Oral antileukemic treatment remains active cancer therapy even when administered at home and the child appears well. Families must understand the current prescribed schedule, monitoring requirements, and whom to contact about missed doses, vomiting, or administration difficulties. Reconcile the actual home routine with the treatment plan because changes and misunderstandings can accumulate over time. Feeling well during maintenance reflects a treatment phase rather than permission to alter therapy independently.

Apply it

During medication reconciliation, a caregiver says doses are skipped whenever the child is tired. The nurse explores the reason, clarifies the prescribed plan with the team, and creates a practical administration routine that addresses the family's concern.

Common pitfall: Calling oral treatment less important because it occurs at home undermines adherence. Missed doses should not trigger an improvised double dose without treatment-team instructions.

Childhood Acute Lymphoblastic Leukemia | NCI · Support for Families: Childhood Cancer | NCI

Symptom Management and Supportive Care26%

28.How should oral hygiene change during cancer treatment?

Gentle oral hygiene reduces plaque and maintains the mucosal environment during treatment. A soft toothbrush and bland rinses are generally preferable to abrasive cleaning or irritating alcohol-containing products, with adjustments for the child's condition. Foam swabs can moisten tissues but do not remove plaque as effectively as brushing. Assess pain, bleeding, mucosal injury, swallowing, and intake; painful mucositis can threaten hydration even when visible lesions seem limited.

Apply it

A caregiver replaces all brushing with foam swabs because the child's mouth is sore. The nurse assesses lesions, bleeding risk, pain, and fluid intake, discusses a gentle individualized cleaning plan, and explains the different roles of brushing and moistening.

Common pitfall: Foam swabs are not equivalent plaque-removal tools. Conversely, rigidly insisting on the usual technique despite severe pain or active injury can make oral care traumatic.

Oral Complications (PDQ®) — Health Professional Version | NCI

29.What must be assessed when an infusion device changes pressure or flow?

A sudden pressure or flow change requires assessment of the child and access site before simply adjusting the pump. Inspect and palpate the peripheral site, compare it with the opposite limb, and ask about burning, stinging, pain, or altered sensation. Leakage, swelling, blanching, or impaired distal perfusion suggest tissue injury. Assess during drug administration and frequently during ongoing infusion. Pump settings cannot establish that fluid remains intravascular, and children with impaired communication need deliberate observational assessment.

Apply it

An infusion slows and the child protects the cannulated arm. Before changing pump limits, the nurse examines the site and distal circulation. New swelling and burning lead to stopping the infusion and initiating extravasation assessment without flushing.

Common pitfall: Restoring the programmed rate does not demonstrate safe access. Sedation, neuropathy, or limited communication can conceal pain, so absence of a complaint cannot replace inspection and palpation.

Peripheral Extravasation Injuries: Initial Management and Washout Procedure | Royal Children's Hospital Melbourne

30.When is a child's self-report the preferred pain measure?

A child who can understand and use an appropriate pain scale should usually provide the primary pain report. Match the tool to developmental and communication abilities rather than selecting solely by chronological age. Behavior, physiologic findings, and caregiver observations add context but do not invalidate a credible self-report. When reliable self-report is unavailable, use an appropriate observational tool and the caregiver's knowledge of the child's baseline pain behaviors.

Apply it

A school-age child uses a validated faces scale consistently and reports significant pain while watching a cartoon. The nurse accepts the report, assesses its location and character, and plans relief rather than substituting an adult's impression.

Common pitfall: Smiling, distraction, or stable vital signs do not prove that pain is absent. For a nonverbal child, unusual stillness or withdrawal may signal pain even without crying.

Acute Pain Management | Royal Children's Hospital Melbourne

31.What transfusion history and product requirements matter before red-cell administration in sickle cell disease?

Before planned transfusion, communicate previous transfusions, reactions, and known antibodies to the blood bank, including records from other hospitals. Red-cell selection in sickle cell disease includes matching beyond ABO and RhD; the NHLBI report specifies C, E, and K antigen matching. Confirm that the issued product meets the child's prescribed compatibility requirements. After discharge, new anemia, jaundice, or pain following transfusion warrants assessment for a delayed hemolytic reaction rather than automatic attribution to vaso-occlusion.

Apply it

A child received blood elsewhere and is scheduled for another transfusion. The nurse obtains the outside transfusion and antibody history for blood-bank review. When the caregiver later reports jaundice and worsening pallor, the nurse communicates the recent transfusion and arranges urgent evaluation.

Common pitfall: ABO compatibility alone does not address all alloimmunization risks. A reaction-free infusion does not exclude delayed hemolysis after the child leaves the treatment unit.

56-364NFULL.pdf

32.What should be reassessed after analgesia?

Reassessment should determine whether pain relief improved comfort and function while checking for treatment-related harm. Use a consistent pain measure when possible and reassess at a time appropriate to the medicine and route. After opioids, sedation and respiratory status are important safety observations. Persistent pain requires reconsideration of the cause and plan; increasing sleepiness is not a substitute for satisfactory analgesia or evidence that the original pain has resolved.

Apply it

After prescribed opioid analgesia, a child is difficult to rouse but still grimaces during movement. The nurse promptly assesses breathing and sedation, obtains assistance, and avoids interpreting reduced activity as proof of successful pain control.

Common pitfall: Documenting only a lower pain score misses adverse effects and function. Repeating analgesia automatically without reviewing excessive sedation can compound respiratory risk and obscure deterioration.

Acute Pain Management | Royal Children's Hospital Melbourne

33.Which contributors should be assessed in cancer-related fatigue?

Cancer-related fatigue can arise from the disease, treatment, anemia, pain, sleep disturbance, emotional distress, nutritional problems, medications, and other medical conditions. Assess its onset, severity, daily pattern, and effect on usual activities before choosing an intervention. Review night waking and daytime sleep because pain and prolonged naps can perpetuate disrupted sleep. The key decision is whether a modifiable contributor or new clinical problem is present.

Apply it

An adolescent stops attending school because of exhaustion. The nurse reviews sleep, pain, mood, medicines, nutrition, and blood-count trends, then coordinates assessment of identified contributors and a tailored activity plan rather than treating inactivity as the only cause.

Common pitfall: Assuming all fatigue is unavoidable treatment burden can miss reversible causes. A normal hemoglobin result does not exclude fatigue from pain, poor sleep, distress, or other treatment effects.

Fatigue (PDQ®) — Health Professional Version | NCI

34.Why must colony-stimulating-factor teaching identify the specific treatment purpose?

Colony-stimulating factors affect selected white-cell populations, and their clinical role depends on the product and regimen. GM-CSF, granulocyte-macrophage colony-stimulating factor, is included with dinutuximab-containing immunotherapy in high-risk neuroblastoma to support immune activity against residual disease. Its presence in that regimen cannot be interpreted solely as treatment of a low blood count. Verify the prescribed factor and treatment phase when explaining its purpose, and continue urgent infection assessment when fever or instability develops.

Apply it

A caregiver asks why GM-CSF remains prescribed during neuroblastoma immunotherapy despite an adequate neutrophil count. The nurse explains its role within the combined immune treatment and confirms the planned product and schedule with the oncology team.

Common pitfall: An adequate count alone does not establish that a prescribed colony-stimulating factor is unnecessary. Conversely, receiving an immune-stimulating medicine does not exclude infection or replace prompt assessment of fever.

Neuroblastoma Treatment (PDQ®) — Health Professional Version | NCI · Fever and Suspected or Confirmed Neutropenia | Royal Children's Hospital Melbourne

35.Why can anthracycline exposure require lifelong cardiac attention?

Anthracyclines can injure myocardium, with dysfunction emerging during treatment or years later. Cumulative exposure and other cardiac risk factors influence follow-up needs, including relevant radiation exposure. A survivor may be asymptomatic before dysfunction becomes clinically apparent, which explains exposure-based surveillance. New exertional intolerance, breathlessness, or edema needs evaluation rather than routine reassurance. Surveillance timing should follow the survivor's specific exposure profile instead of a universal interval.

Apply it

A survivor treated with an anthracycline feels healthy and asks why cardiac follow-up continues. The nurse explains delayed myocardial injury and confirms that the treatment summary and individualized surveillance plan are available to the current clinician.

Common pitfall: A normal past echocardiogram does not permanently remove cardiac risk. Conversely, the cancer diagnosis alone cannot determine the appropriate screening schedule without treatment-exposure information.

Late Effects of Treatment for Childhood Cancer | NCI · Children's Oncology Group Long-Term Follow-Up Guidelines, Version 6.0, October 2023

36.Which exposures suggest renal late-effect surveillance?

Nephrotoxic chemotherapy, radiation involving the kidneys, and loss of renal tissue can create persistent renal risk. Surveillance considers blood pressure, renal function, and other findings relevant to the specific exposure, including tubular abnormalities when indicated. A survivor can have clinically important renal injury without dramatic urinary symptoms. Treatment history therefore guides assessment, and hypertension or an abnormal laboratory trend should not be dismissed because the child appears well.

Apply it

A survivor with prior nephrectomy and nephrotoxic treatment has repeatedly elevated blood pressure but no urinary complaints. The nurse identifies a renal follow-up concern and communicates the exposure history rather than waiting for pain or visible urine changes.

Common pitfall: Normal urine appearance does not establish normal kidney function. Using one screening test for every exposure can also miss differences between glomerular and tubular injury.

Children's Oncology Group Long-Term Follow-Up Guidelines, Version 6.0, October 2023

37.How can treatment-related hearing loss appear in school?

Platinum chemotherapy and certain radiation exposures can cause hearing impairment, sometimes affecting higher frequencies before everyday conversation becomes obviously difficult. A child may appear inattentive, misunderstand instructions, or struggle in noisy classrooms. Exposure-based audiologic surveillance helps distinguish hearing difficulty from motivation or behavior. The practical decision is to assess hearing and educational access rather than assuming that adequate conversation in a quiet clinic excludes a meaningful deficit.

Apply it

A child previously treated with cisplatin follows conversation in clinic but repeatedly misses classroom instructions. The nurse reviews hearing-surveillance results and requests audiologic and school support assessment instead of attributing the change solely to attention problems.

Common pitfall: A child can compensate in quiet settings while struggling in noise. Waiting for obvious conversational deafness may delay educational accommodations and recognition of treatment-related impairment.

Children's Oncology Group Long-Term Follow-Up Guidelines, Version 6.0, October 2023

38.Why should growth patterns be reviewed after cranial irradiation?

Radiation involving the hypothalamic-pituitary region can disrupt hormone regulation and affect growth and pubertal development. Serial growth patterns are therefore more informative than one height measurement. Reduced growth velocity, unexpected pubertal timing, or other endocrine symptoms should prompt exposure-informed evaluation. A short child may have several possible explanations, but previous cranial irradiation is a meaningful clue that endocrine dysfunction deserves consideration rather than automatic attribution to family stature.

Apply it

A child's height percentile falls steadily after cranial irradiation while peers continue their expected growth. The nurse reviews serial measurements and pubertal history, then communicates the pattern for endocrine assessment rather than waiting for a single extreme measurement.

Common pitfall: One normal height measurement can hide a declining growth trajectory. Endocrine surveillance should follow relevant exposure and development rather than symptoms alone or a fixed age assumption.

Children's Oncology Group Long-Term Follow-Up Guidelines, Version 6.0, October 2023 · Late Effects of Treatment for Childhood Cancer | NCI

39.How should reproductive risk be discussed after gonadotoxic treatment?

Some chemotherapy and radiation exposures can impair gonadal function and future fertility, with risk influenced by treatment type, dose, age, and the organs exposed. Counseling should distinguish fertility from pubertal development and sexual health. Normal puberty or menstruation does not prove preserved fertility, and possible fertility impairment does not establish infertility. Use the treatment history to guide specialist assessment and provide developmentally appropriate opportunities to discuss reproductive goals.

Apply it

An adolescent survivor assumes regular menstruation guarantees future fertility after gonadotoxic treatment. The nurse explains the limits of that inference, reviews the exposure history, and offers confidential, developmentally appropriate discussion and referral for individualized reproductive counseling.

Common pitfall: Avoid promising either fertility or infertility from outward development alone. Fertility concerns also should not replace broader discussion of sexual health, relationships, and the survivor's own goals.

Late Effects of Treatment for Childhood Cancer | NCI · Children's Oncology Group Long-Term Follow-Up Guidelines, Version 6.0, October 2023

40.Which school changes can signal neurocognitive late effects?

CNS-directed treatments can affect attention, processing speed, memory, and executive function. Difficulties may become more visible as schoolwork grows complex, even when earlier performance was satisfactory. Assess the pattern and treatment history rather than equating new academic struggle with low effort. Neuropsychological evaluation can clarify strengths and needs and support educational planning. Hearing, sleep, mood, and other contributors should also be considered because several problems can produce similar classroom difficulties.

Apply it

A survivor previously treated with CNS-directed therapy manages simple assignments but struggles with planning multistep projects. The nurse explores the change, reviews hearing and sleep concerns, and supports referral for neuropsychological assessment and appropriate school accommodations.

Common pitfall: Earlier normal grades do not exclude later-emerging difficulties. Labeling the child unmotivated before assessing treatment-related and other contributors can delay effective support and increase distress.

Late Effects of Treatment for Childhood Cancer | NCI · Children's Oncology Group Long-Term Follow-Up Guidelines, Version 6.0, October 2023

41.When does musculoskeletal pain require assessment beyond deconditioning?

Cancer treatment can affect bone health and joint integrity, including corticosteroid-associated osteonecrosis in susceptible patients. Persistent focal pain, restricted movement, or an altered gait deserves evaluation rather than automatic attribution to inactivity. Reduced bone mineral density and osteonecrosis are different problems: one concerns bone strength, while the other involves bone injury associated with impaired blood supply. The location and pattern of symptoms help determine the appropriate diagnostic assessment.

Apply it

An adolescent with substantial corticosteroid exposure develops persistent hip pain and a limp. The nurse reports the focal symptoms and treatment history for evaluation rather than recommending that the adolescent simply exercise through presumed loss of conditioning.

Common pitfall: General exercise advice is insufficient for unexplained focal joint pain. A bone-density assessment alone also does not answer every question about painful joint pathology or osteonecrosis.

Late Effects of Treatment for Childhood Cancer | NCI

42.How can palliative care support a child receiving curative treatment?

Palliative care addresses physical symptoms, psychological distress, communication, and practical or spiritual concerns associated with serious illness. It can accompany treatment intended to cure or control cancer. Referral is appropriate when symptom burden or decision complexity exceeds what the current plan manages well; it does not require a prediction that death is imminent. The care team can support both disease-directed goals and the child's daily comfort and participation.

Apply it

A child receiving curative therapy has persistent pain, nausea, and family distress despite routine interventions. The nurse recommends palliative consultation to improve symptom control and communication while the oncology team continues the planned cancer-directed treatment course.

Common pitfall: Waiting until all anticancer options end unnecessarily restricts access to symptom expertise. Palliative consultation also does not automatically change resuscitation decisions or the chosen treatment goal.

Palliative Care in Cancer | NCI

43.Why should supplements be included in medication reconciliation?

Foods, herbs, vitamins, and dietary supplements can alter drug metabolism, transport, or biologic effects and thereby change cancer-treatment exposure or toxicity. A product's natural origin does not establish compatibility with therapy, and different formulations can contain different ingredients. Ask specifically and without judgment about everything taken, including teas and products suggested by relatives. Review the actual ingredients with the treatment team instead of giving a blanket assurance based on the product category.

Apply it

A caregiver starts an herbal mixture advertised for immunity but does not consider it a medicine. The nurse asks for the ingredient list and coordinates interaction review with the pharmacist before the family continues adding it to treatment.

Common pitfall: A dismissive response can discourage disclosure. Conversely, absence of a documented interaction is not proof of safety when the ingredients, formulation, or supporting evidence are uncertain.

Cancer Therapy Interactions With Foods and Dietary Supplements | NCI

Pediatric Hematologic and Oncologic Emergencies21%

44.Why is suspected febrile neutropenia time critical?

Neutropenia reduces the ability to contain infection, and inflammatory signs can be subtle. Fever in an at-risk child requires prompt assessment and empiric antibacterial treatment according to the pediatric pathway. Do not wait for laboratory confirmation of neutropenia when the history and clinical situation indicate risk. Hemodynamic instability, altered responsiveness, or respiratory compromise requires immediate escalation. Obtaining investigations should proceed efficiently without allowing avoidable delay in treatment.

Apply it

A child recently treated with myelosuppressive chemotherapy arrives febrile and lethargic, with the blood count still pending. The nurse activates urgent assessment and the febrile-neutropenia pathway rather than waiting for the neutrophil result before initiating care.

Common pitfall: A well-appearing interval or lack of a local infection focus does not establish safety. Antipyretic response also cannot distinguish a harmless fever from evolving invasive infection.

Fever and Suspected or Confirmed Neutropenia | Royal Children's Hospital Melbourne

45.How should cultures and empiric antibiotics be coordinated in high-risk febrile neutropenia?

Obtain blood cultures from every central-line lumen and consider a concurrent peripheral blood culture. Collect specimens before antibiotics when this can be done promptly, without delaying treatment for difficult sampling or pending laboratory results. Initial high-risk empiric therapy requires antipseudomonal activity. Recommended monotherapy options include an appropriate antipseudomonal beta-lactam, fourth-generation cephalosporin, or antipseudomonal carbapenem, selected using local susceptibility data. Reserve a second Gram-negative agent or a glycopeptide for clinical instability, suspected resistant infection, or relevant local resistance patterns.

Apply it

A febrile child with a multilumen central line develops poor perfusion while peripheral culture attempts fail. Coordinate cultures from the available central-line lumens and immediate prescribed antipseudomonal antibiotics. Alert the team to the instability because it can justify additional Gram-negative coverage or a glycopeptide. Continued pursuit of a peripheral specimen must not postpone treatment.

Common pitfall: Broad-spectrum labeling alone does not establish adequate high-risk coverage: the regimen must cover Pseudomonas. Conversely, routinely adding a glycopeptide or multiple Gram-negative agents to every initial regimen ignores the guideline's indications for combination treatment. Culture collection should support timely treatment, never become a prerequisite that delays it.

Guideline for the Management of Fever and Neutropenia in Children with Cancer and/or Undergoing Hematopoietic Stem-Cell Transplantation · Fever and Suspected or Confirmed Neutropenia | Royal Children's Hospital Melbourne

46.Which biochemical pattern suggests tumor lysis syndrome?

Rapid malignant-cell breakdown releases potassium, phosphate, and nucleic acids. Nucleic-acid metabolism raises uric acid, while phosphate can bind calcium and contribute to hypocalcemia. The characteristic pattern is hyperkalemia, hyperphosphatemia, hyperuricemia, and falling calcium, with possible acute kidney injury, arrhythmia, or seizures. Interpret laboratory trends alongside tumor burden, treatment timing, and clinical status. Tumor lysis can occur spontaneously as well as after anticancer treatment.

Apply it

Soon after therapy begins for bulky leukemia, a child has rising potassium, phosphate, uric acid, and creatinine with falling calcium. The nurse recognizes a linked tumor-lysis pattern and escalates monitoring and treatment rather than addressing each result in isolation.

Common pitfall: Expecting calcium to rise reverses the usual pattern. Also, waiting for symptoms can miss a dangerous biochemical progression before arrhythmia, seizure, or overt renal failure develops.

Prevention of Tumour Lysis Syndrome | eviQ, Cancer Institute NSW

47.How do tumor-lysis prevention strategies target different risks?

Tumor-lysis prevention starts with risk assessment using disease burden, expected treatment response, baseline laboratory findings, and renal function. Hydration and close monitoring support management of released solutes. Allopurinol reduces formation of new uric acid, whereas rasburicase breaks down existing uric acid; these are different mechanisms. Rasburicase has an important contraindication in G6PD deficiency. Choice of preventive measures should reflect the child's risk rather than a universal regimen for every cancer.

Apply it

A child with a highly treatment-sensitive bulky malignancy already has elevated uric acid and impaired renal function. The nurse recognizes that preventing new uric-acid formation differs from removing existing uric acid and checks the planned risk-specific strategy.

Common pitfall: Allopurinol does not directly clear uric acid already present. Routine urine alkalinization is also not a harmless default because it can worsen calcium-phosphate precipitation risk.

Prevention of Tumour Lysis Syndrome | eviQ, Cancer Institute NSW

48.When should acute chest syndrome be suspected in sickle cell disease?

Acute chest syndrome is a serious pulmonary complication of sickle cell disease that can involve chest pain, fever, cough, breathing difficulty, and reduced oxygenation. A new pulmonary infiltrate is an important diagnostic feature in the appropriate clinical setting. Infection, pulmonary vaso-occlusion, and other mechanisms can contribute. New respiratory symptoms during a pain episode require urgent hospital assessment rather than an assumption that all discomfort is uncomplicated vaso-occlusive pain.

Apply it

A hospitalized child with sickle cell pain develops fever, cough, and a new oxygen requirement. The nurse urgently reports the change and prepares for pulmonary evaluation rather than attributing the symptoms solely to rib pain or anxiety.

Common pitfall: A pain crisis does not exclude a simultaneous pulmonary emergency. Respiratory deterioration should not be managed only by increasing analgesia without reassessing oxygenation and underlying causes.

Complications of SCD: Acute Chest Syndrome | CDC

49.Why does splenic sequestration cause rapid circulatory compromise?

Splenic sequestration traps a substantial amount of blood within an enlarging spleen, reducing circulating blood volume and causing acute anemia. In a child with sickle cell disease, sudden splenic enlargement, pallor, weakness, or unusual sleepiness should raise concern. Rapid progression can lead to shock. Caregiver teaching should connect the child's individualized spleen-assessment instructions with immediate action for concerning enlargement or systemic symptoms rather than waiting for a routine appointment.

Apply it

A caregiver reports that a young child with sickle cell disease is suddenly pale and unusually sleepy, and the abdomen seems larger. The nurse directs immediate emergency evaluation for possible splenic sequestration rather than scheduling a routine assessment.

Common pitfall: Abdominal enlargement with pallor is not simply another pain episode. Absence of fever does not make a sudden anemia-and-volume-loss pattern safe for home observation.

Complications of SCD: Splenic Sequestration | CDC

50.Which changes suggest spinal cord compression?

Tumor extension into the spinal canal can compress neural structures and cause progressive neurologic injury. New back pain, limb weakness, altered gait, sensory change, or bowel and bladder dysfunction are warning features, particularly with a tumor capable of intraspinal extension such as neuroblastoma. Urgent assessment is needed before deficits become irreversible. The presence of constipation does not make new weakness a routine gastrointestinal side effect or justify delaying neurologic evaluation.

Apply it

A child with paraspinal neuroblastoma develops a new limp and difficulty passing urine. The nurse escalates urgently for possible spinal cord compression and communicates the timing of motor and bladder changes rather than treating them as separate problems.

Common pitfall: Waiting for complete paralysis sacrifices an opportunity for earlier intervention. Drug-related neuropathy is a competing explanation, but focal progression with bladder dysfunction demands urgent evaluation.

Neuroblastoma Treatment (PDQ®) — Health Professional Version | NCI

51.Why can sedation be dangerous with a symptomatic mediastinal mass?

An anterior mediastinal mass can compress the airway, great vessels, or heart. Supine positioning, sedation, or anesthesia may worsen compression by altering airway tone, ventilation, and cardiovascular mechanics. Orthopnea, positional cough, stridor, or difficulty lying flat are high-risk clues. Maintain the child's position of comfort and obtain coordinated oncology, anesthesia, and critical-care planning. Obtaining diagnostic tissue must be balanced against the immediate risk of cardiopulmonary collapse.

Apply it

A child with a mediastinal mass becomes breathless when lying flat before a planned biopsy. The nurse maintains the position that eases breathing and urgently requests multidisciplinary review before routine preprocedure sedation or forced supine positioning.

Common pitfall: Anxiety is not an adequate explanation for reproducible positional respiratory distress. A familiar sedation routine can become hazardous when the mass compromises airway or vascular structures.

Anterior Mediastinal Mass: Getting the Diagnosis Guideline | Alberta Children's Hospital

52.What is the immediate response to suspected extravasation?

Extravasation is leakage of an infused substance into surrounding tissue, potentially causing substantial injury depending on the agent. Stop the infusion immediately and do not flush the line, because flushing can deliver more substance into tissue. Initially retain access for assessment, possible aspiration, or agent-specific management while obtaining help. Subsequent measures depend on the substance and injury; a single warm-or-cold compress rule does not apply to every infusion.

Apply it

During a peripheral infusion, a child reports burning and the site becomes swollen. The nurse stops the infusion, avoids flushing, keeps the cannula available initially, and promptly obtains the agent-specific extravasation plan and expert assessment.

Common pitfall: Flushing to test patency can worsen tissue exposure. Immediate removal of the cannula may also eliminate access needed for aspiration or prescribed local management.

Peripheral Extravasation Injuries: Initial Management and Washout Procedure | Royal Children's Hospital Melbourne

53.When does abdominal pain during asparaginase therapy suggest pancreatitis?

Asparaginase-associated pancreatitis should be considered when a treated child develops persistent or severe abdominal pain, often with nausea and vomiting. The prescribing information directs evaluation with pancreatic enzymes and appropriate clinical assessment, with drug interruption and subsequent decisions based on confirmed findings and severity. The discriminating cue is sustained pancreatic-type illness in an exposed child, rather than brief nausea alone. Other abdominal emergencies remain possible and require examination.

Apply it

A child recently given an asparaginase product develops severe persistent upper abdominal pain and repeated vomiting. The nurse promptly reports possible pancreatitis and prepares for laboratory and clinical evaluation rather than administering an antiemetic as the sole response.

Common pitfall: A recent chemotherapy dose does not make severe pain an expected harmless effect. Conversely, abdominal symptoms alone do not establish pancreatitis without appropriate clinical and laboratory evaluation.

RYLAZE — Prescribing Information | DailyMed

54.How can cytokine release syndrome resemble infection?

Activated immune cells can release large amounts of inflammatory cytokines after CAR T-cell treatment, producing fever and potentially hypotension, hypoxia, and organ dysfunction. These findings can resemble sepsis, and infection can coexist with inflammatory toxicity. Treatment timing is a useful clue, but it is not a reason to exclude infection. New fever with circulatory or respiratory compromise requires urgent assessment through the cellular-therapy emergency plan and parallel consideration of infectious causes.

Apply it

After CAR T-cell infusion, a child develops fever, falling blood pressure, and increasing oxygen needs. The nurse activates urgent cellular-therapy assessment and communicates the timing while supporting evaluation for both cytokine-mediated toxicity and possible infection.

Common pitfall: Labeling every postinfusion fever as cytokine release syndrome can delay infection treatment. Stable early findings also do not guarantee that inflammatory toxicity will remain mild.

T-cell Transfer Therapy | NCI · Fever and Suspected or Confirmed Neutropenia | Royal Children's Hospital Melbourne

55.Which joint symptoms suggest a hemophilia bleed?

Bleeding into a joint can begin with discomfort, tingling, warmth, or reluctance to move before marked swelling appears. In a child with hemophilia, an acutely painful joint or reduced use of a limb warrants prompt assessment and the prescribed bleeding-management plan. Repeated joint bleeding can cause lasting damage. Lack of a witnessed injury does not exclude a bleed because episodes may occur after minor trauma or without an obvious trigger.

Apply it

A child with hemophilia avoids bearing weight and says one ankle feels warm, although swelling is minimal. The nurse recognizes a possible early joint bleed and promptly contacts the hematology team rather than requiring visible bruising first.

Common pitfall: Waiting for dramatic swelling can delay treatment. A normal platelet count does not exclude a joint bleed caused by deficient coagulation-factor activity in hemophilia.

About Hemophilia | CDC

Psychosocial Dimensions of Care8%

56.How should procedure preparation match a child's development?

Preparation works best when explanations match the child's developmental understanding, prior experiences, and immediate concerns. Use concrete language, honest sensory descriptions, play or demonstration when helpful, and manageable choices that do not imply the procedure is optional when it is required. Ask what the child expects before correcting misconceptions. Predictable support and coping plans can reduce uncertainty, while promises that a painful procedure will not hurt can damage trust.

Apply it

A young child believes a port procedure is punishment for misbehavior. The nurse corrects the belief with simple language, demonstrates the sequence using play materials, and helps the child choose a realistic coping strategy and support person.

Common pitfall: More technical detail does not necessarily improve understanding. Offering a false choice about a required procedure can also create conflict when the child's refusal cannot be honored.

Support for Families: Childhood Cancer | NCI

57.How can adolescents participate meaningfully in care decisions?

Adolescents need opportunities to ask questions, express priorities, and practice self-management while retaining appropriate family support. Speak directly to the adolescent and assess understanding instead of conducting every discussion only with caregivers. Offer suitable privacy and explain confidentiality boundaries according to the setting and applicable requirements. Respectful inquiry about identity, relationships, and future goals helps identify concerns that may otherwise remain hidden during discussions dominated by treatment logistics.

Apply it

An adolescent stops contributing when caregivers answer every question. The nurse directs developmentally appropriate questions to the adolescent, offers an opportunity for private discussion, and works with the family to support gradually increasing participation in everyday care decisions.

Common pitfall: Adolescent participation does not require removing supportive caregivers from every discussion. Conversely, family involvement should not erase the young person's own concerns, preferences, or developing self-management skills.

Support for Families: Childhood Cancer | NCI · CPHON Test Content Outline

58.Why do siblings need their own information and support?

Siblings may experience fear, jealousy, guilt, loneliness, or disrupted routines while family attention centers on the ill child. They need truthful explanations suited to their age, opportunities to ask questions, and reassurance about misconceptions such as causing the illness. Maintaining meaningful school, social, and family connections supports adjustment. Their outward independence does not establish that they understand the illness or are coping without distress, especially when caregivers are stretched.

Apply it

A sibling begins missing activities and says asking for attention would burden the family. The nurse helps caregivers arrange predictable individual time, age-appropriate information, and school or counseling support while preserving activities that matter to the sibling.

Common pitfall: Praising a sibling only for being undemanding can conceal unmet needs. Giving identical information to every sibling also overlooks developmental differences and distinct concerns.

Support for Siblings When a Brother or Sister Has Cancer | NCI

59.How should practical barriers be explored before labeling nonadherence?

Missed visits or difficulty following treatment may reflect transportation problems, work obligations, housing instability, cost, language barriers, or caregiver overload. Ask about the specific task that failed and what made it difficult. Social workers, school teams, community organizations, and other resources can help construct a workable plan. The clinical goal is reliable access and treatment participation; moral judgments about motivation do not identify the barrier or supply a solution.

Apply it

A caregiver repeatedly misses morning appointments because the only available ride arrives later. The nurse explores scheduling and transport resources with the social worker, then confirms a feasible plan instead of repeating instructions about the importance of attendance.

Common pitfall: Documenting unwillingness before assessing access can misrepresent the family and worsen engagement. A resource referral is incomplete unless the family can actually use the proposed service.

Support for Families: Childhood Cancer | NCI

60.How can grief support respect culture and individual preferences?

Grief can begin before death as children and families experience losses of health, routine, independence, or expected futures. Expressions of grief vary across individuals, developmental stages, beliefs, and family traditions. Ask what support, rituals, communication, and spiritual involvement the family wants rather than inferring preferences from group identity. Continued support may involve psychosocial, palliative, spiritual, or community resources and should allow family members to express different needs without judgment.

Apply it

During worsening illness, one caregiver wants spiritual support while another prefers quiet practical planning. The nurse asks each person about priorities, coordinates requested resources, and supports the child's own questions without assuming one response represents the entire family.

Common pitfall: Visible emotion is not a reliable measure of love or distress. Cultural knowledge can inform respectful questions but cannot substitute for asking this family's preferences.

Palliative Care in Cancer | NCI · Support for Families: Childhood Cancer | NCI

What to focus on during revision

The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.

  • Link emergency cues to mechanisms: fever with immune suppression, tumor-lysis laboratory trends, positional respiratory distress, new neurologic deficits, and sickle-cell cardiopulmonary changes.
  • Distinguish treatment classes by what they do: cytotoxic drugs, factor replacement, red-cell transfusion, donor transplantation, engineered T cells, surgery, and targeted radiopharmaceutical treatment.
  • Connect treatment exposures with organ-specific surveillance, including cardiac, renal, auditory, endocrine, reproductive, and neurocognitive effects.
  • Use lineage, tumor biology, residual disease, grade, stage, neuroblastoma studies, and sickle-cell laboratory trends to answer distinct clinical questions.
  • Practise device assessment, transfusion-history and compatibility decisions, and explanation of colony-stimulating factors within their prescribed treatment context.
  • Assess symptoms through function and developmental ability: drinking with oral injury, credible pain self-report, fatigue contributors, and safe analgesic reassessment.
  • Practise family-centered decisions that address adolescent participation, sibling needs, confirmed access to care, and individual grief preferences.

A practical preparation plan

1. Map strengths against the complete outline

Mark each official subtopic as confident, uncertain, or unfamiliar. This guide is selective; the official outline remains the full scope. Extend study to additional pediatric malignancies and hematologic disorders, regulatory practice standards, central-line infection prevention and occlusion management, bedside transfusion monitoring, growth-factor administration schedules, and emergencies such as typhlitis, thrombosis, and increased intracranial pressure.

2. Build paired treatment-toxicity comparisons

Explain why vincristine suggests neuropathy and constipation, asparaginase suggests pancreatic and coagulation complications, allogeneic transplantation introduces donor immune effects, and CAR T cells can trigger inflammatory toxicity. Compare simple and exchange transfusion by their effects on red-cell mass and HbS proportion.

3. Rehearse time-critical decisions

For each emergency, state the decisive cue, immediate nursing action, information needed, and action that could worsen the situation. Include antibiotics without avoidable delay, no flushing during extravasation, and position-of-comfort precautions with a symptomatic mediastinal mass.

4. Work the questions before reading explanations

Select one answer and write the cue supporting it. After review, explain why each alternative is less appropriate. Classify errors as mechanism, cue recognition, prioritization, or interpretation, then revisit the corresponding concept.

5. Retrieve and integrate across settings

Use the flashcards over spaced sessions, explaining the reasoning aloud. Finish with cases that combine acute treatment, supportive care, developmental needs, and transition planning so knowledge remains usable beyond isolated definitions.

Use your sample score as a starting point

The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.

Start the free sample

Official sources and updates

Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.